Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.61 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.61 |
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.59 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.58 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.58 |
| ▸ | KRAS | P01116 | 9/20 | 0.58 |
| ▸ | HINT1 | P49773 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26624608 | 0.94 | TGM2 (0.64) | TAS1R3TAS1R1NT5ETGM2KRAS | |
| SCHEMBL26208257 | 0.92 | TAS1R3 (0.63) | TAS1R3TAS1R1NT5ETGM2IMPDH2 | |
| SCHEMBL26622892 | 0.89 | NT5E (0.66) | TAS1R3TAS1R1NT5ETGM2IMPDH2 | |
| SCHEMBL26624255 | 0.88 | TAS1R3 (0.62) | TAS1R3TAS1R1NT5ETGM2IMPDH2 | |
| SCHEMBL26623556 | 0.88 | NT5E (0.65) | TAS1R3TAS1R1NT5ETGM2IMPDH2 | |
| SCHEMBL26207954 | 0.88 | NT5E (0.65) | TAS1R3TAS1R1NT5ETGM2IMPDH2 | |
| SCHEMBL26208112 | 0.88 | NT5E (0.67) | TAS1R3TAS1R1NT5ETGM2IMPDH2 | |
| SCHEMBL26211540 | 0.88 | HINT1 (0.57) | NT5ETGM2KRASHINT1 | |
| SCHEMBL26209245 | 0.86 | NT5E (0.67) | TAS1R3TAS1R1NT5ETGM2IMPDH2 | |
| SCHEMBL20673346 | 0.86 | NT5E (0.69) | TAS1R3TAS1R1NT5ETGM2IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| WO-2023159930-A1 | COMPOUND FOR RNA CAPPING AND APPLICATION OF COMPOUND | 广州市恒诺康医药科技有限公司 | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | RNGTT, RNMT, NSUN2 | TAS1R3 3664/4885TAS1R1 3824/4885NT5E 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.